Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | MPI | P34949 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL181949 | 0.87 | MPI (0.36) | PAX8MPIUSP2SLCO1B1 | |
| SCHEMBL165933 | 0.87 | MPI (0.36) | PAX8MPIUSP2SLCO1B1 | |
| SCHEMBL7155133 | 0.87 | MPI (0.36) | PAX8MPIUSP2SLCO1B1 | |
| SCHEMBL19948 | 0.87 | MPI (0.36) | PAX8MPIUSP2SLCO1B1 | |
| SCHEMBL7148553 | 0.83 | MPI (0.46) | MPI | |
| SCHEMBL4601534 | 0.83 | MPI (0.46) | MPI | |
| SCHEMBL17555601 | 0.80 | LMNA (0.42) | MPIUSP2SLCO1B1 | |
| SCHEMBL7695502 | 0.80 | LMNA (0.42) | MPIUSP2SLCO1B1 | |
| SCHEMBL27772430 | 0.80 | LMNA (0.42) | MPIUSP2SLCO1B1 | |
| SCHEMBL19514770 | 0.80 | LMNA (0.42) | MPIUSP2SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2637687-B1 | VACCINES COMPRISING NON-SPECIFIC NUCLEOSIDE HYDROLASE AND STEROL 24-C-METHYLTRANSFERASE (SMT) POLYPEPTIDES FOR THE TREATMENT AND DIAGNOSIS OF LEISHMANIASIS | INFECTIOUS DISEASE RES INST (US) | 2021-01-06 | — | — | EP | claimed |
| CN-108403659-A | A kind of hard emulsion receives microballoon and its preparation method and application | 中国科学院过程工程研究所 | 2018-08-17 | — | — | CN | claimed |
| CN-108324938-A | A kind of granular pattern adjuvant and its preparation method and application | 中国科学院过程工程研究所 | 2018-07-27 | — | — | CN | claimed |
| WO-2017013603-A1 | ADJUNTIVE IMMUNOTHERAPY FOR THE PREVENTION OR TREATMENT OF INFECTIOUS DISEASE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-01-26 | — | — | WO | claimed |
| EP-2852414-A1 | MENINGOCOCCUS SEROGROUP X CONJUGATE | Novartis AG (CH) | 2015-04-01 | — | — | EP | claimed |
| WO-2013174832-A1 | MENINGOCOCCUS SEROGROUP X CONJUGATE | NOVARTIS AG (CH) | 2013-11-28 | — | — | WO | claimed |
| US-20240197844-A1 | PEPTIDE VACCINES USABLE FOR HYPERCHOLESTEROLEMIA RELATED DISEASES | AFFIRIS CVD GMBH (AT) | 2024-06-20 | — | — | US | disclosed |
| US-11980657-B2 | Peptide vaccines for hypercholesterolemia related diseases | AFFIRIS CVD GMBH (AT) | 2024-05-14 | — | — | US | disclosed |
| EP-4288076-A1 | VIRAL CONSTRUCTS FOR USE IN ENHANCING T-CELL PRIMING DURING VACCINATION | Geovax, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230109142-A1 | CORONA VIRUS VACCINE | IMMUNOR AS (NO) | 2023-04-06 | — | — | US | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| EP-4103587-A1 | CORONA VIRUS VACCINE | Immunor AS (NO) | 2022-12-21 | — | — | EP | disclosed |
| WO-2001034617-A2 | AMINOALKYL GLUCOSAMINIDE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
| US-6113918-A | IMMUNOLOGY | RIBI IMMUNOCHEM RESEARCH, INC. (US) | 2000-09-05 | — | — | US | disclosed |
| EP-0983286-A1 | AMINOALKYL GLUCOSAMINE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998050399-A1 | AMINOALKYL GLUCOSAMINE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 1998-11-12 | — | — | WO | disclosed |
| US-5352811-A | To produce homoallylic alcohol, acylation, oxidation of double bond | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-10-04 | — | — | US | disclosed |
| US-5158941-A | Lipid A analog as stimulant for production of interleukin-1 in human monocytes and tumor cell growth inhibitor | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-10-27 | — | — | US | disclosed |
| WO-1990003186-A1 | GRAM-NEGATIVE BACTERIAL ENDOTOXIN BLOCKING MONOCLONAL ANTIBODIES | CETUS CORPORATION (US) | 1990-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109142-A1 | CORONA VIRUS VACCINE | CALCA, HCFC1, STING1 | PAX8 3273/4885MPI 3578/4885USP2 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.